Antibiotic resistance is a problem that impacts tens of millions of people each year worldwide. According to the CDC, „more than 2.8 million antibiotic-resistant infections occur in the United States each year, and more than 35,000 people die as a result.“ Drug-resistant infections are threatening advances in surgery, wound healing, cancer treatment, organ transplants and many other areas of modern medicine by decreasing our ability to control infections.
August 31, 2022
Antibiotic resistance is a problem that impacts tens of millions of people each year worldwide. According to the CDC, „more than 2.8 million antibiotic-resistant infections occur in the United States each year, and more than 35,000 people die as a result.“ Drug-resistant infections are threatening advances in surgery, wound healing, cancer treatment, organ transplants and many other areas of modern medicine by decreasing our ability to control infections.
As the nation and world face this daunting challenge, newly published work from researchers at the University of Minnesota could significantly and positively impact how we fight bacterial infections that are resistant to more traditional antibiotics, particularly in immunocompromised populations. The research, recently published in PLOS ONE by co-authors Sven-Ulrik Gorr, a professor in the School of Dentistry, and Elizabeth Hirsch, an associate professor in the College of Pharmacy, examined an antibacterial peptide developed in the School of Dentistry and its potential impact on drug-resistant bacteria.
